M. Ekenel Et Al. , "Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study," 42nd European-Society-for-Medical-Oncology Congress (ESMO) , vol.28, Madrid, Spain, 2017
Ekenel, M. Et Al. 2017. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study. 42nd European-Society-for-Medical-Oncology Congress (ESMO) , (Madrid, Spain).
Ekenel, M., Aydın, E., CIL, I., ZIRTILOGLU, A., TURAL, D., & KARABULUT, S., (2017). Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study . 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain
Ekenel, Meltem Et Al. "Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study," 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 2017
Ekenel, Meltem Et Al. "Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study." 42nd European-Society-for-Medical-Oncology Congress (ESMO) , Madrid, Spain, 2017
Ekenel, M. Et Al. (2017) . "Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study." 42nd European-Society-for-Medical-Oncology Congress (ESMO) , Madrid, Spain.
@conferencepaper{conferencepaper, author={Meltem EKENEL Et Al. }, title={Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study}, congress name={42nd European-Society-for-Medical-Oncology Congress (ESMO)}, city={Madrid}, country={Spain}, year={2017}}